

QIAGEN expands integrated coronavirus NGS solutions

20 August 2020 | News

QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research



QIAGEN has launched the innovative QIAseq SARS-CoV-2 Primer Panel for next-generation sequencing (NGS) of the novel coronavirus genome, along with integrated analysis and interpretation workflows for insights into the evolution and spread of the virus that causes COVID-19 disease.

The new products are an expansion of QIAGEN's broad offering of sample technologies, diagnostic tests and instruments, and research tools for use in the global effort to combat the COVID-19 pandemic.

QIAGEN's new QIAseq SARS-CoV-2 Primer Panel provides optimized, single-day workflows to prepare libraries for sequencing as researchers use NGS to track viral genome changes in studying the epidemiology of virus outbreaks.

The two-step process uses advanced QIAseq technologies to conduct reverse transcription and cDNA synthesis from a viral RNA sample, then generate libraries compatible with Illumina sequencing platforms.

The workflow is faster and has lower-input requirements compared to hybrid capture solutions.